In the Spotlight...

An immune cell map of human lung adenocarcinoma development reveals an anti-tumoral role of the Tfh-dependent tertiary lymphoid structure

Liu et al. generated a time-resolved scRNAseq map of the immune dynamic during human lung adenocarcinoma development from initiation through invasion, and found that while NK cells reduced, CD4+ T cel...

Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides

Ferreira et al. utilized circular RNA-derived open-reading frames, which harbor a canonical ATG start codon and span the back-splice junction region, to expand the repertoire of neoantigens to be expl...

Modeling T cell temporal response to cancer immunotherapy rationalizes development of combinatorial treatment protocols

Barboy et al. leveraged scRNAseq to track temporal transitions in T cell phenotypes across compartments in multiple mouse tumor models, identifying 7 novel, functional programs that spanned a continuu...

Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors

López et al. investigated the impact of cross-presenting type 1 dendritic cells (cDC1), with or without DC therapy (Flt3L + anti-CD40), in a mouse lung tumor model with a defined pattern of endogenou...

Previous Digests

T cells and macrophages collaborate to overcome MHC-I loss-induced immune deserts

March 20, 2024

Loss of MHC class I expression on tumor cells is a frequently observed immunotherapy resistance mechanism. The increased use of immune checkpoint blockade (ICB) for the treatment of solid tumors has resulted in more therapy-resistant MHC-I-deficient tumors. To better...

CD4+ T cells help cDC1s provide CD8+ T cells with a license to kill

March 13, 2024

CD4+ T helper cells can stimulate CD8+ T cell responses by interacting with dendritic cells (DCs) through a process termed “DC licensing”. The conventional type 1 DC (cDC1) subset has been identified as the essential DC subtype for this...

ESMO Targeted Anticancer Therapies Congress 2024

March 6, 2024

The ACIR team attended the ESMO Targeted Anticancer Therapies Congress 2024 in Paris, France. This week’s extensive special feature covers select talks from the conference. We have organized the content by topics below. Keynote lecture on tumor neoantigensYardena Samuels...

Watch ACIR in action

In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.

Watch the 3-minute video explaining ACIR's mission and goal:

In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.

Watch the 6-minute segment on the story behind your favorite digest here:

About ACIR

ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.

Ed Fritsch

Ed Fritsch

Ute Burkhardt

Ute Burkhardt

Lauren Hitchings

Lauren Hitchings

Gaelle Lespinasse-Llambi

Gaelle Lespinasse-Llambi

Maartje Wouters

Maartje Wouters

Alex Najibi

Alex Najibi

Katherine J. Turner

Katherine J. Turner

Stan Wolf

Stan Wolf

Paula Hochman

Paula Hochman

Shishir Pant

Shishir Pant

Nathan Suek

Nathan Suek

Morgan Janes

Morgan Janes

Current Sponsors

Close Modal

Small change for you. Big change for us!

This Thanksgiving season, show your support for cancer research by donating your change.

In less than a minute, link your credit card with our partner RoundUp App.

Every purchase you make with that card will be rounded up and the change will be donated to ACIR.

All transactions are securely made through Stripe.